Obsidian Therapeutics, Inc. OBX
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-7.22
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 |
|---|---|---|
| Revenue | $0 | $0 |
| R&D | $86.1M | $73.2M |
| SG&A | $19.6M | $18.1M |
| Total operating expenses | $105.7M | $91.3M |
| Operating income | -$105.7M | -$91.3M |
| Pre-tax income | -$100.6M | -$83.1M |
| Income tax | $0 | $0 |
| Net income | -$100.6M | -$83.1M |
| EPS, basic | -7.22 | -6.47 |
| EPS, diluted | -7.22 | -6.47 |
| Shares, diluted (wtd. avg.) | $13.9M | $12.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 |
|---|---|---|
| Operating cash flow | -$90.4M | -$75.0M |
| Depreciation and amortisation | $1.5M | $1.5M |
| Stock-based compensation | $8.9M | $7.1M |
| Capital expenditure | $73.0K | $779.0K |
| Investing cash flow | $81.0M | -$53.9M |
| Financing cash flow | $20.0K | $162.5M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-374729.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |